Disclosure Of First-Time Adoption [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166143

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Disclosure of first-time adoption [text block]
Disclosure of comparative information prepared under previous GAAP [text block]
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity
39,069,000 EUR
80,761,000 EUR
476,000 EUR
121,513,000 EUR
140,000 EUR
2,162,000 EUR
4,460,000 EUR
53,909,000 EUR
1,136,000 EUR
140,000 EUR
121,513,000 EUR
476,000 EUR
476,000 EUR
1,622,000 EUR
1,136,000 EUR
4,460,000 EUR
121,513,000 EUR
1,622,000 EUR
65,381,000 EUR
64,246,000 EUR
140,000 EUR
55,045,000 EUR
4,460,000 EUR
54,805,000 EUR
476,000 EUR
48,056,000 EUR
3,827,000 EUR
103,693,000 EUR
2,391,000 EUR
129,000 EUR
Comprehensive income
15,380,000 EUR
15,380,000 EUR
11,906,000 EUR
10,770,000 EUR
10,770,000 EUR
Profit (loss)
15,380,000 EUR
11,906,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.